Information Provided By:
Fly News Breaks for February 10, 2020
INO
Feb 10, 2020 | 12:55 EDT
Piper Sandler analyst Christopher Raymond says he remains a buyer of Overweight-rated Inovio shares after the company announced that the IND for INO-3107 has been accepted and will advance into a Phase 1/2 trial for the treatment of recurrent respiratory papillomatosis. Raymond says that while management had indicated the Phase 2 could be pivotal, it appears the FDA is looking for more patient data before giving the sign-off on a registrational study, but reminds investors that the INO-3107 program was not even on the radar at this time last year. While INO-3107 remains an unmodeled opportunity for him at this point, he thinks INO-3107 could be worth ~$5/share if successful and views 2020 as a "catalyst rich" year for Inovio.
News For INO From the Last 2 Days
There are no results for your query INO